ClinicalTrials.gg
CompletedNCT03990805Updated Sep 28, 2022

A Phase 3 Study to Evaluate the Efficacy and Safety of JointStem in Treatment of Osteoarthritis

A Phase 3 interventional study of JOINTSTEM and saline in Degenerative Arthritis and Knee Osteoarthritis, sponsored by R-Bio. Completed at 13 sites in Korea, Republic of. Open to participants aged 20 Years to 100 Years. Per ClinicalTrials.gov, last updated 2022-09-28.

Primary conditionOsteoarthritis, KneeRegistry: OsteoarthritisReclassifiedWhy we changed it
Registry
Osteoarthritis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Osteoarthritis, Knee
Why
  1. The study's listed conditions name Osteoarthritis, Knee, a narrower term within Osteoarthritis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by R-Bio · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
20 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 96 studies in Osteoarthritis, Knee with a site in Korea, Republic of — 13 open to participants now, 21 under way, 4 of them phase 3. Osteoarthritis, Knee · Korea, Republic of.

Enrollment
19th of 85
260 · median 124
Started
2019
with 4 others
Phase 3
18 of 96
1 open now
Registered
54th of 96
by date
Lead sponsor
5 of 96
R-Bio

Among the 96 studies in Osteoarthritis, Knee with a site in Korea, Republic of, this one is the 19th largest by enrollment of the 85 interventional ones that give a count, is one of 5 that started in 2019, is one of 18 in phase 3, and was the 54th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

13 of the 96 studies in Osteoarthritis, Knee with a site in Korea, Republic of are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 20 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 96 studies in Osteoarthritis, Knee with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the efficacy and safety of autologous Adipose Tissue derived Mesenchymal stem cells (JOINTSTEM®) in patient with severe Knee Osteoarthritis.

Read the detailed description

JOINTSTEM is injectables for an OA treatment that uses autologous adipose-derived mesenchymal stem cells. As it does not use allogenic tissues and is cultured without additional genetic modification, it is classified as 'autologous cell therapy' and is completely free of immunologic rejection.

It primarily aims to improve joint function. The intra-articular injection of JOINTSTEM is expected to stimulate the regeneration of cartilage, and to innovatively improve joint function with cartilage regeneration.

The subjects of this therapy were patients with K\&L grade 3 aged 20 or older.

This study is a double-blind, randomized, placebo controlled study with two arms to evaluate JOINTSTEM as a treatment for subjects with osteoarthritis. Following a 2-week screening period, approximately 260 patients will be randomly assigned into one of the following two arms in a 1:1 ratio (1 JointStem : 1 placebo control). After each patient completes 6-month visit (Visit 5) and the data management team confirms all data have no issue, the individual database will be locked and the blinding will be open for the statistical analysis.

03

Conditions studied

  • Degenerative Arthritis
  • Knee Osteoarthritis

Browse trials for

Keywords

  • Stem Cell
  • Adipose tissue derived mesenchymal stem cell
  • osteoarthritis
  • degenerative arthritis
  • biostar
  • Rbio
04

In context

Osteoarthritis, Knee Reclassified

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

This study's enrollment of 260 is above the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.

Browse Osteoarthritis, Knee studies →

Lead sponsor

R-Bio is the lead sponsor of 16 studies on the registry; 1 is open to participants now.

Compared within Osteoarthritis, Knee, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Osteoarthritis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
20 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 20 and older, male and female
  2. Patients must consent in writing to participate in the study by signing and dating an document
  3. Diagnosis of degenerative arthritis of class 1-3 by ACR(American College of Rheumatology Criteria) Global functional criteria
  4. Diagnosis of Kellgren and Lawrence grade 3 by radiographic criteria
  5. Patients suitable for one of three conditions of 'diagnostic criteria for osteoarthritis of knee' based on ACR guideline

    • clinical and inspectional opinion
    • clinical and radiographic opinion
    • clinical opinion
  6. Patients who has joint pain ≥ 50mm on 100mm VAS (Visual Analog Scale) at Screening
  7. Patient who has WOMAC score ≥ 1000 at Screening
  8. No improvement with persisting knee pain at least for 12 weeks (3 months) by nonoperational therapy before Screening

Exclusion criteria

Exclusion Criteria:

  1. Patients who have pregnancy plans within this trial period or childbearing age patients who do not agree to maintain status through appropriate contraception methods

    • Appropriate contraception method: Use of condom, contraceptive sponges, foam, diaphragm, intrauterine device etc.
    • Periodic abstinence(e.g. methods of predicting ovulation) and moderation are not considered as appropriate contraception method.
    • Not allowed to use hormonal contraceptives
    • Childbearing age female patients, exclude menopausal female (amenorrhea for more than 24 months after the last menstruation) or female who has no possibility of pregnency by surgical sterilization operation, can participate in this study only determined negative in pregnancy test
  2. Pregnant women or lactating mothers
  3. Patients with (BMI) > 35
  4. Patients with positive human immunodeficiency (), (HBV), (HCV), syphilis at screening indicative of current of pass infection
  5. Patients with other disease including

    • Septic arthritis, Rheumatoid or Inflammatory joint disease, Gout, Reccurent pseudogout, Paget disease, Articular fractures, Ochronosis, Acromegaly, Hemochromatosis, Wilson's disease,Osteochondromatosis, Hereditary disorder, Genetic disorder of collagen
  6. Patients who are diagnosed with malignant tumor in the past or present
  7. Patients who have diseases including

    • Cardiac disorder (Myocardial infarction, Coronary artery bypass graft, Arrhythmia and other severe Cardiac disorder etc.)
    • Resistant hypertension (systolic blood pressure > 160mmHg or diastolic pressure > 100mmHg at Screening)
    • Kidney disease (Chronic renal failure, Glomerulonephritis etc.)
    • Liver disease (Hepatocirrhosis, Fatty liver, acute or chronic liver disease etc.)
    • Endocrinopathy (Thyroiditis, Diabetes insipidus, Cushing disease etc.)
  8. Patients who have significant lab abnormalities
  9. Patients who have severe pain in other areas that can affect the judgement of knee joint symptom
  10. Patients who underwent any arthroscopic surgery on the injection site within 6 months of the screening visit date, or scheduled to perform any surgery during the clinical trial period
  11. Patients who received any drug by intra-articular injection(hyaluronic acid or etc.) for treatment within 6 months prior to Screening
  12. Patients who experienced as stem cell therapy or blood product injection(PRP, Prolo injection etc.)
  13. Patients who received treatment within 14 days prior to Screening including(But, patients who had wash-out-period can participate in this study)

    • Take medicines including composition of Glucosamine, Chondretin sulphate and Diacerhein etc.
    • Take phytotherapeutic agent or Chinese medicine for osteoarthritis
    • Take antiinflammatory analgesic drug, NSAIDs (prescription/nonprescription pharmaceuticals) etc. (Patients who have 3 days of wash-out-period after they took acetaminophen can participate in the study)
    • Take oral steroids
    • Physical therapy or Chinese medical treatment(cupping, acupuncture, moxibustion etc.)
  14. Patients with penicillin reactions
  15. Patients with skin diseases or infections in the area of the injection site
  16. Patients who have abnormal flail over grade 2 flail knee test of anterior to posterior and varus/valgus lesion at physical examination
  17. Patients who have difficulty in taking MRI because of metal materials (cardiac pacemaker or clip of cerebral artery etc.) in their body or claustrophobia -but, patients with metal materials that are not affected by magnetic field can participate in this study
  18. Patients who have difficulty in liposuction or local anesthesia
  19. Patients who have alcohol, drug abuse history
  20. Patients who have severe neurologic and psychiatric disorders that affect clinical trials
  21. Patients who had participated in other clinical trials within 12 weeks prior to this study
  22. Patients who the principal investigator considers inappropriate for the clinical trial due to any other reasons than those listed above
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
260 participants (actual)

Study arms

  • Experimental
    JOINTSTEM

    Autologous Adipose Tissue derived MSCs

    Biological: JOINTSTEM

  • Placebo comparator
    saline

    saline

    Drug: saline

Interventions

  • BiologicalJOINTSTEM

    JOINTSTEM Autologous Adipose Tissue derived MSCs 1x10\^8cells/(saline), 1 time injection

    Also known as: Autologous Adipose Tissue derived MSCs

  • Drugsaline

    saline, 1 time injection

07

What researchers measure

Primary outcomes

  1. Change of Western Ontario and McMaster Universities Osteoarthritis Index(WOMAC) scores from baseline

    Pain, stiffness, and physical function of the knee will be measured by the WOMAC score * Score range is 1. 0-20 for Pain 2. 0-8 for Stiffness 3. 0-68 for Pysical Function * Higher scores on the WOMAC indicate wors pain, stiffness, and functional limitations

    Time frame: 12 weeks, 24 weeks

  2. Change of Visual Analog Scale (VAS) scores from baseline

    Pain of knee will be measured by the 100mm VAS -Score range is from 0-4mm(no pain) to 75-100mm(severe pain)

    Time frame: 12 weeks, 24 weeks

Secondary outcomes

  1. WOMAC 3 subscale score

    Pain, stiffness, and physical function of the knee will be measured by the Western Ontario and McMaster Universities (WOMAC)

    Time frame: 12 weeks, 24 weeks

  2. VAS score

    Pain of knee will be measured by the 100mm Visual Analog Scale (VAS)

    Time frame: 12 weeks, 24 weeks

  3. KOOS

    Symptoms, pain and functionality of the knee joint will be evaluated via the Knee Injury and Osteoarthritis Outcome Score (KOOS) -Score range is from 0(extreme symptoms) to 100(no symptoms)

    Time frame: 12 weeks, 24 weeks

  4. SF-36

    The SF(Short Form)-36 Health Survey is a 36-item, patient-reported survey of patient health.

    Time frame: 12 weeks, 24 weeks

  5. IKDC

    Symptoms, sports activities, and function of the knee will be measured by the International Knee Documentation Committee (IKDC)

    Time frame: 12weeks, 24 weeks

  6. Measuring of Kellgren-Lawrence grade

    Measuring of Kellgren-Lawrence grade through X-ray

    Time frame: 12 weeks, 24 weeks

  7. Measuring of Femoro-tibial anatomical angle(FTA)

    Measuring of FTA through X-ray

    Time frame: 12 weeks, 24 weeks

  8. Measuring of Hip-Knee-Ankle angle(HKA)

    Measureing of HKA through X-ray

    Time frame: 12 weeks, 24 weeks

  9. Measuring of Joint Space Width

    measuring Joint Space Width through X-ray

    Time frame: 12 weeks, 24 weeks

  10. MRI scan

    MRI perform to measure Modified WORMS (Whole-Organ Magnetic Resonance Imaging Score)

    Time frame: 12 weeks, 24 weeks

  11. Use of rescue medication

    Frequency and total amount of rescue medication administration will be measured.

    Time frame: 12 weeks, 24 weeks

08

Study locations

13 sites
  • Chungbuk National University Hospital
    Cheongju-si, 28644, Korea, Republic of
  • Yeungnam University Hospital
    Daegu, 42415, Korea, Republic of
  • Keimyung University Dongsan Medical Center
    Daegu, 42601, Korea, Republic of
  • Chonbuk National University Hospital
    Jeonju, 54907, Korea, Republic of
  • Gyeongsang National University Hospital
    Jinju-si, 52727, Korea, Republic of
  • Kyunghee University Medical Center
    Seoul, 02447, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Yonsei University Health System
    Seoul, 03722, Korea, Republic of
  • KyungHee University Gangdong Hospital
    Seoul, 05278, Korea, Republic of
  • Gangnam Severance Hospital
    Seoul, 06273, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • Seoul St. Mary's Hospital
    Seoul, 06591, Korea, Republic of
  • Chunang University Hospital
    Seoul, 06973, Korea, Republic of
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Dec 2020, 18 months.

Of 65 industry-sponsored phase 3 interventional studies under Osteoarthritis, Knee, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 27. This study's 18 months is close to that.

Counting every sponsor, half of 101 studies reached it within 22 months; a quarter within 15 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2019
First posted
Jun 19, 2019
StartActual
Jun 11, 2019
Primary completionActual
Dec 15, 2020
CompletionActual
Dec 15, 2020
Last update
Sep 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03990805
Lead sponsor
R-Bio
Responsible party
Sponsor
First posted
Jun 19, 2019
Start date
Jun 11, 2019
Primary completion
Dec 15, 2020
Completion
Dec 15, 2020
Last update
Sep 28, 2022

Study contacts

KANGIL KIM, M.D., Ph.D.
principal investigator · KyungHee University Gangdong Hospital
WOOSUK LEE, M.D., Ph.D.
principal investigator · Gangnam Severance Hospital
SUNCHUL HWANG, M.D., Ph.D.
principal investigator · Gyeongsang National University Hospital
SANGJUN SONG, M.D., Ph.D.
principal investigator · Kyunghee University Medical Center
KICHEOR BAE, M.D., Ph.D.
principal investigator · Keimyung University Dongsan Medical Center
YOUNGWAN MOON, M.D., Ph.D.
principal investigator · Samsung Medical Center
JUHONG LEE, M.D., Ph.D.
principal investigator · Chonbuk National University Hospital
HANJUN LEE, M.D., Ph.D.
principal investigator · Chunang University Hospital
EUISUNG CHOI, M.D., Ph.D.
principal investigator · Chungbuk National University Hospital
YONG IN, M.D., Ph.D.
principal investigator · Seoul St. Mary's Hospital
KWANKYU PARK, M.D., Ph.D.
principal investigator · Yonsei University
OOGJIN SHON, M.D., Ph.D.
principal investigator · Yeungnam University Hospital
MYUNGCHUL LEE, M.D., Ph.D.
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion